Fresenius Medical Care (NYSE:FMS) announced an annual dividend on Thursday, May 10th, Zacks reports. Stockholders of record on Tuesday, May 22nd will be paid a dividend of 0.436 per share on Monday, June 4th. This represents a dividend yield of 0.86%. The ex-dividend date is Monday, May 21st.
Fresenius Medical Care has raised its dividend payment by an average of 0.2% per year over the last three years and has raised its dividend annually for the last 2 consecutive years. Fresenius Medical Care has a dividend payout ratio of 15.6% indicating that its dividend is sufficiently covered by earnings. Analysts expect Fresenius Medical Care to earn $2.85 per share next year, which means the company should continue to be able to cover its $0.37 annual dividend with an expected future payout ratio of 13.0%.
Shares of Fresenius Medical Care traded down $0.26, hitting $50.37, during trading on Wednesday, MarketBeat.com reports. 1,605 shares of the stock traded hands, compared to its average volume of 151,380. The firm has a market cap of $31.28 billion, a price-to-earnings ratio of 22.91, a P/E/G ratio of 2.77 and a beta of 0.62. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.26 and a quick ratio of 1.01. Fresenius Medical Care has a twelve month low of $50.31 and a twelve month high of $50.53.
Fresenius Medical Care (NYSE:FMS) last announced its quarterly earnings results on Thursday, May 3rd. The company reported $0.49 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.70 by ($0.21). Fresenius Medical Care had a net margin of 7.29% and a return on equity of 11.09%. The firm had revenue of $3.98 billion for the quarter, compared to analyst estimates of $4.07 billion. During the same quarter in the prior year, the firm earned $1.01 earnings per share. The firm’s quarterly revenue was down 12.6% compared to the same quarter last year. equities research analysts predict that Fresenius Medical Care will post 2.63 earnings per share for the current year.
Several equities research analysts recently weighed in on the company. Royal Bank of Canada restated a “neutral” rating on shares of Fresenius Medical Care in a report on Thursday, May 3rd. DZ Bank restated a “buy” rating on shares of Fresenius Medical Care in a report on Thursday, April 5th. Zacks Investment Research upgraded Fresenius Medical Care from a “hold” rating to a “buy” rating and set a $62.00 target price for the company in a report on Thursday, January 18th. Finally, Deutsche Bank upgraded Fresenius Medical Care from a “hold” rating to a “buy” rating in a report on Tuesday, April 24th. One analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $54.67.
Fresenius Medical Care Company Profile
Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the U.S.
Receive News & Ratings for Fresenius Medical Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care and related companies with MarketBeat.com's FREE daily email newsletter.